webinar register page

Webinar banner
Exploring bevacizumab response in low-grade glioma
In this training, we’ll help you navigate the interesting intersection of the tumor microenvironment, mutation status and gene expression to identify plausible activators affecting bevacizumab targets in low-grade glioma (LGG).

During this training, you will learn about:
• The tools used to identify key genes in LGG
• How to choose specific gene alterations
• The intersection between immune response tumor mutations
• How to identify other key genes of interest
• How to build a network tying all these elements together

Oct 11, 2022 01:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information
DISCLAIMER: QIAGEN may use your personal information for the purpose of participation in the webinar, informing you about future events and for internal business and marketing purposes. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) solely for the purposes of data hosting, marketing calls and QIAGEN email distribution. You may unsubscribe at any time. Your data will be processed in compliance with applicable privacy laws including the EU General Data Protection Regulation. For further details please refer to our Privacy Policy.